{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:34:26Z","timestamp":1794029666546,"version":"4.8.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1038\/s41401-023-01169-5","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:03:05Z","timestamp":1697439785000},"page":"646-659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Reexamining the effects of drug loading on the in vivo performance of PEGylated liposomal doxorubicin"],"prefix":"10.1038","volume":"45","author":[{"given":"Yi-fei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Er-can","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-qi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-xiu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-hao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-you","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"1169_CR1","first-page":"5","volume":"392","author":"R Langer","year":"1998","unstructured":"Langer R. Drug delivery and targeting. Nature. 1998;392:5\u201310.","journal-title":"Nature"},{"key":"1169_CR2","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1126\/science.1095833","volume":"303","author":"TM Allen","year":"2004","unstructured":"Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818\u201322.","journal-title":"Science"},{"key":"1169_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16:71.","journal-title":"J Nanobiotechnol"},{"key":"1169_CR4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0022-2836(64)80115-7","volume":"8","author":"AD Bangham","year":"1964","unstructured":"Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol. 1964;8:660\u20138.","journal-title":"J Mol Biol"},{"key":"1169_CR5","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0140-6736(74)90682-5","volume":"1","author":"G Gregoriadis","year":"1974","unstructured":"Gregoriadis G, Wills EJ, Swain CP, Tavill AS. Drug-carrier potential of liposomes in cancer chemotherapy. Lancet. 1974;1:1313\u20136.","journal-title":"Lancet"},{"key":"1169_CR6","doi-asserted-by":"publisher","first-page":"853","DOI":"10.4103\/0973-1482.139267","volume":"10","author":"S Rivankar","year":"2014","unstructured":"Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014;10:853\u20138.","journal-title":"J Cancer Res Ther"},{"key":"1169_CR7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.2165\/11207510-000000000-00000","volume":"71","author":"ST Duggan","year":"2011","unstructured":"Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi\u2019s sarcoma. Drugs. 2011;71:2531\u201358.","journal-title":"Drugs"},{"key":"1169_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil\u00ae\u2013the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117\u201334.","journal-title":"J Control Release"},{"key":"1169_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4155\/ppa-2019-0020","volume":"9","author":"N Akhtar","year":"2020","unstructured":"Akhtar N, Mohammed SA, Singh V, Abdellatif AA, Mohammad HA, Ahad A, et al. Liposome-based drug delivery of various anticancer agents of synthetic and natural product origin: a patent overview. Pharm Pat Anal. 2020;9:87\u2013116.","journal-title":"Pharm Pat Anal."},{"key":"1169_CR10","first-page":"297","volume":"1","author":"ML Immordino","year":"2006","unstructured":"Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed. 2006;1:297\u2013315.","journal-title":"Int J Nanomed"},{"key":"1169_CR11","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.2217\/nnm-2020-0152","volume":"15","author":"P Maiti","year":"2020","unstructured":"Maiti P. Drug-delivery vehicles and their efficiency toward cancer treatment. Nanomed (Lond). 2020;15:1637\u201340.","journal-title":"Nanomed (Lond)"},{"key":"1169_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1517\/17425247.2011.553216","volume":"8","author":"K Kita","year":"2011","unstructured":"Kita K, Dittrich C. Drug delivery vehicles with improved encapsulation efficiency: taking advantage of specific drug\u2013carrier interactions. Expert Opin Drug Deliv. 2011;8:329\u201342.","journal-title":"Expert Opin Drug Deliv"},{"key":"1169_CR13","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","volume":"19","author":"S Sindhwani","year":"2020","unstructured":"Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020;19:566\u201375.","journal-title":"Nat Mater"},{"key":"1169_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/17435390.2017.1292371","volume":"11","author":"C Gerecke","year":"2017","unstructured":"Gerecke C, Edlich A, Giulbudagian M, Schumacher F, Zhang N, Said A, et al. Biocompatibility and characterization of polyglycerol-based thermoresponsive nanogels designed as novel drug-delivery systems and their intracellular localization in keratinocytes. Nanotoxicology. 2017;11:267\u201377.","journal-title":"Nanotoxicology"},{"key":"1169_CR15","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1023\/A:1016012520276","volume":"13","author":"H Park","year":"1996","unstructured":"Park H, Park K. Biocompatibility issues of implantable drug delivery systems. Pharmacol Res. 1996;13:1770\u20136.","journal-title":"Pharmacol Res"},{"key":"1169_CR16","doi-asserted-by":"publisher","first-page":"13015","DOI":"10.1021\/acsnano.9b05679","volume":"13","author":"Y Tang","year":"2019","unstructured":"Tang Y, Wang X, Li J, Nie Y, Liao G, Yu Y, et al. Overcoming the reticuloendothelial system barrier to drug delivery with a \u201cDon\u2019t-Eat-Us\u201d strategy. ACS Nano. 2019;13:13015\u201326.","journal-title":"ACS Nano"},{"key":"1169_CR17","doi-asserted-by":"publisher","first-page":"e2000673","DOI":"10.1002\/smll.202000673","volume":"16","author":"X Liu","year":"2020","unstructured":"Liu X, Tang I, Wainberg ZA, Meng H. Safety considerations of cancer nanomedicine\u2014a key step toward translation. Small. 2020;16:e2000673.","journal-title":"Small"},{"key":"1169_CR18","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.2147\/IJN.S139687","volume":"12","author":"W Brand","year":"2017","unstructured":"Brand W, Noorlander CW, Giannakou C, De Jong WH, Kooi MW, Park MV, et al. Nanomedicinal products: a survey on specific toxicity and side effects. Int J Nanomed. 2017;12:6107\u201329.","journal-title":"Int J Nanomed"},{"key":"1169_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.nano.2014.11.003","volume":"11","author":"G Caracciolo","year":"2015","unstructured":"Caracciolo G. Liposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines. Nanomedicine. 2015;11:543\u201357.","journal-title":"Nanomedicine"},{"key":"1169_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jconrel.2019.05.030","volume":"305","author":"F Zahednezhad","year":"2019","unstructured":"Zahednezhad F, Saadat M, Valizadeh H, Zakeri-Milani P, Baradaran B. Liposome and immune system interplay: challenges and potentials. J Control Release. 2019;305:194\u2013209.","journal-title":"J Control Release"},{"key":"1169_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.actbio.2021.07.074","volume":"134","author":"N Onishchenko","year":"2021","unstructured":"Onishchenko N, Tretiakova D, Vodovozova E. Spotlight on the protein corona of liposomes. Acta Biomater. 2021;134:57\u201378.","journal-title":"Acta Biomater"},{"key":"1169_CR22","doi-asserted-by":"publisher","first-page":"e2100370","DOI":"10.1002\/adhm.202100370","volume":"10","author":"K Yang","year":"2021","unstructured":"Yang K, Reker-Smit C, Stuart MCA, Salvati A. Effects of protein source on liposome uptake by cells: Corona composition and impact of the excess free proteins. Adv Health Mater. 2021;10:e2100370.","journal-title":"Adv Health Mater"},{"key":"1169_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/08982100802309552","volume":"18","author":"SM Moghimi","year":"2008","unstructured":"Moghimi SM, Hamad I. Liposome-mediated triggering of complement cascade. J Liposome Res. 2008;18:195\u2013209.","journal-title":"J Liposome Res"},{"key":"1169_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1081\/LPR-64971","volume":"15","author":"X Yan","year":"2005","unstructured":"Yan X, Scherphof GL, Kamps JA. Liposome opsonization. J Liposome Res. 2005;15:109\u201339.","journal-title":"J Liposome Res"},{"key":"1169_CR25","doi-asserted-by":"publisher","first-page":"113897","DOI":"10.1016\/j.addr.2021.113897","volume":"176","author":"JD Clogston","year":"2021","unstructured":"Clogston JD. The importance of nanoparticle physicochemical characterization for immunology research: what we learned and what we still need to understand. Adv Drug Deliv Rev. 2021;176:113897.","journal-title":"Adv Drug Deliv Rev"},{"key":"1169_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2017.01.002","volume":"519","author":"R Luo","year":"2017","unstructured":"Luo R, Li Y, He M, Zhang H, Yuan H, Johnson M, et al. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations. Int J Pharm. 2017;519:1\u201310.","journal-title":"Int J Pharm"},{"key":"1169_CR27","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","volume":"37","author":"I Judson","year":"2001","unstructured":"Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXILI\/CAELYXI) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37:870\u20137.","journal-title":"Eur J Cancer"},{"key":"1169_CR28","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.biopha.2017.09.059","volume":"95","author":"A Shafei","year":"2017","unstructured":"Shafei A, El-Bakly W, Sobhy A, Wagdy O, Reda A, Aboelenin O, et al. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother. 2017;95:1209\u201318.","journal-title":"Biomed Pharmacother"},{"key":"1169_CR29","unstructured":"DOXIL\u00ae (doxorubicin HCl liposome injection) for intravenous infusion, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/050718s029lbl.pdf (2007)."},{"key":"1169_CR30","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","volume":"136","author":"M Lotem","year":"2000","unstructured":"Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000;136:1475\u201380.","journal-title":"Arch Dermatol"},{"key":"1169_CR31","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1021\/acsnano.2c00423","volume":"16","author":"Y Li","year":"2022","unstructured":"Li Y, Lofchy L, Wang G, Gaikwad H, Fujita M, Simberg D. PEGylated liposomes accumulate in the areas relevant to skin toxicities via passive extravasation across \u201cLeaky\u201d Endothelium. ACS Nano. 2022;16:6349\u201358.","journal-title":"ACS Nano"},{"key":"1169_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0005-2736(93)90105-9","volume":"1151","author":"G Haran","year":"1993","unstructured":"Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993;1151:201\u201315.","journal-title":"Biochim Biophys Acta"},{"key":"1169_CR33","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1021\/acs.nanolett.0c04806","volume":"21","author":"Y Chu","year":"2021","unstructured":"Chu Y, Tang W, Zhang Z, Li C, Qian J, Wei X, et al. Deciphering protein Corona by scFv-based affinity chromatography. Nano Lett. 2021;21:2124\u201331.","journal-title":"Nano Lett"},{"key":"1169_CR34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jconrel.2020.12.047","volume":"330","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Chu Y, Li C, Tang W, Qian J, Wei X, et al. Anti-PEG scFv corona ameliorates accelerated blood clearance phenomenon of PEGylated nanomedicines. J Control Release. 2021;330:493\u2013501.","journal-title":"J Control Release"},{"key":"1169_CR35","doi-asserted-by":"publisher","first-page":"10107","DOI":"10.1021\/acs.nanolett.1c03946","volume":"21","author":"W Tang","year":"2021","unstructured":"Tang W, Zhang Z, Li C, Chu Y, Qian J, Ying T, et al. Facile separation of PEGylated liposomes enabled by anti-PEG scFv. Nano Lett. 2021;21:10107\u201313.","journal-title":"Nano Lett"},{"key":"1169_CR36","doi-asserted-by":"crossref","unstructured":"Choi WG, Kim DK, Shin Y, Park R, Cho YY, Lee JY, et al. Liquid chromatography-tandem mass spectrometry for the simultaneous determination of doxorubicin and its metabolites doxorubicinol, doxorubicinone, doxorubicinolone, and 7-deoxydoxorubicinone in mouse plasma. Molecules. 2020;25:1254.","DOI":"10.3390\/molecules25051254"},{"key":"1169_CR37","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1021\/acsomega.7b01235","volume":"3","author":"X Wei","year":"2018","unstructured":"Wei X, Shamrakov D, Nudelman S, Peretz-Damari S, Nativ-Roth E, Regev O, et al. Cardinal role of intraliposome doxorubicin-sulfate nanorod crystal in doxil properties and performance. ACS Omega. 2018;3:2508\u201317.","journal-title":"ACS Omega"},{"key":"1169_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"1169_CR39","doi-asserted-by":"publisher","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","volume":"88","author":"BM Chen","year":"2016","unstructured":"Chen BM, Su YC, Chang CJ, Burnouf PA, Chuang KH, Chen CH, et al. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal Chem. 2016;88:10661\u20136.","journal-title":"Anal Chem"},{"key":"1169_CR40","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","volume":"138","author":"TJ Povsic","year":"2016","unstructured":"Povsic TJ, Lawrence MG, Lincoff AM, Mehran R, Rusconi CP, Zelenkofske SL, et al. Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J Allergy Clin Immunol. 2016;138:1712\u20135.","journal-title":"J Allergy Clin Immunol"},{"key":"1169_CR41","doi-asserted-by":"publisher","first-page":"14779","DOI":"10.1021\/acsnano.0c02821","volume":"14","author":"H Wang","year":"2020","unstructured":"Wang H, Ding T, Guan J, Liu X, Wang J, Jin P, et al. Interrogation of Folic Acid-functionalized nanomedicines: the regulatory roles of plasma proteins reexamined. ACS Nano. 2020;14:14779\u201389.","journal-title":"ACS Nano"},{"key":"1169_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jconrel.2020.01.018","volume":"319","author":"T Ding","year":"2020","unstructured":"Ding T, Guan J, Wang M, Long Q, Liu X, Qian J, et al. Natural IgM dominates in vivo performance of liposomes. J Control Release. 2020;319:371\u201381.","journal-title":"J Control Release"},{"key":"1169_CR43","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","volume":"20","author":"M Mohamed","year":"2019","unstructured":"Mohamed M, Abu Lila AS, Shimizu T, Alaaeldin E, Hussein A, Sarhan HA, et al. PEGylated liposomes: immunological responses. Sci Technol Adv Mater. 2019;20:710\u201324.","journal-title":"Sci Technol Adv Mater"},{"key":"1169_CR44","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/wnan.1339","volume":"7","author":"Q Yang","year":"2015","unstructured":"Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7:655\u201377.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"1169_CR45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","volume":"154-155","author":"GT Kozma","year":"2020","unstructured":"Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154-155:163\u201375.","journal-title":"Adv Drug Deliv Rev"},{"key":"1169_CR46","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s13238-010-0125-8","volume":"1","author":"LA Tan","year":"2010","unstructured":"Tan LA, Yu B, Sim FC, Kishore U, Sim RB. Complement activation by phospholipids: the interplay of factor H and C1q. Protein Cell. 2010;1:1033\u201349.","journal-title":"Protein Cell"},{"key":"1169_CR47","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/bab.1291","volume":"62","author":"M Kawanishi","year":"2015","unstructured":"Kawanishi M, Hashimoto Y, Shimizu T, Sagawa I, Ishida T, Kiwada H. Comprehensive analysis of PEGylated liposome-associated proteins relating to the accelerated blood clearance phenomenon by combination with shotgun analysis and conventional methods. Biotechnol Appl Biochem. 2015;62:547\u201355.","journal-title":"Biotechnol Appl Biochem"},{"key":"1169_CR48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.7150\/thno.18078","volume":"7","author":"X Sun","year":"2017","unstructured":"Sun X, Yan X, Jacobson O, Sun W, Wang Z, Tong X, et al. Improved tumor uptake by optimizing liposome based RES blockade strategy. Theranostics. 2017;7:319\u201328.","journal-title":"Theranostics"},{"key":"1169_CR49","doi-asserted-by":"publisher","first-page":"E10871","DOI":"10.1073\/pnas.1713390114","volume":"114","author":"AJ Tavares","year":"2017","unstructured":"Tavares AJ, Poon W, Zhang YN, Dai Q, Besla R, Ding D, et al. Effect of removing Kupffer cells on nanoparticle tumor delivery. Proc Natl Acad Sci USA. 2017;114:E10871\u2013E80.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1169_CR50","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/JLB.3RI0519-161R","volume":"106","author":"R Blandino","year":"2019","unstructured":"Blandino R, Baumgarth N. Secreted IgM: new tricks for an old molecule. J Leukoc Biol. 2019;106:1021\u201334.","journal-title":"J Leukoc Biol"},{"key":"1169_CR51","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.","journal-title":"Front Immunol"},{"key":"1169_CR52","doi-asserted-by":"publisher","first-page":"e1803335","DOI":"10.1002\/adma.201803335","volume":"31","author":"M Hadjidemetriou","year":"2019","unstructured":"Hadjidemetriou M, McAdam S, Garner G, Thackeray C, Knight D, Smith D, et al. The human in vivo biomolecule Corona onto PEGylated liposomes: a proof-of-concept clinical study. Adv Mater. 2019;31:e1803335.","journal-title":"Adv Mater"},{"key":"1169_CR53","doi-asserted-by":"publisher","first-page":"15723","DOI":"10.1021\/acsnano.0c06679","volume":"14","author":"Y Ju","year":"2020","unstructured":"Ju Y, Kelly HG, Dagley LF, Reynaldi A, Schlub TE, Spall SK, et al. Person-specific biomolecular Coronas modulate nanoparticle interactions with immune cells in human blood. ACS Nano. 2020;14:15723\u201337.","journal-title":"ACS Nano"},{"key":"1169_CR54","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41565-018-0344-3","volume":"14","author":"VP Vu","year":"2019","unstructured":"Vu VP, Gifford GB, Chen F, Benasutti H, Wang G, Groman EV, et al. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles. Nat Nanotechnol. 2019;14:260\u20138.","journal-title":"Nat Nanotechnol"},{"key":"1169_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05384-1","volume":"9","author":"J Guan","year":"2018","unstructured":"Guan J, Shen Q, Zhang Z, Jiang Z, Yang Y, Lou M, et al. Enhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption. Nat Commun. 2018;9:2982.","journal-title":"Nat Commun"},{"key":"1169_CR56","doi-asserted-by":"crossref","unstructured":"Neun B, Barenholz Y, Szebeni J, Dobrovolskaia M. Understanding the role of anti-PEG antibodies in the complement activation by Doxil in vitro. Molecules. 2018;23:1700.","DOI":"10.3390\/molecules23071700"},{"key":"1169_CR57","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jconrel.2006.08.017","volume":"115","author":"T Ishida","year":"2006","unstructured":"Ishida T, Atobe K, Wang X, Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J Control Release. 2006;115:251\u20138.","journal-title":"J Control Release"},{"key":"1169_CR58","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.imbio.2012.08.274","volume":"218","author":"T Shimizu","year":"2013","unstructured":"Shimizu T, Ishida T, Kiwada H. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology. 2013;218:725\u201332.","journal-title":"Immunobiology"},{"key":"1169_CR59","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cell.2018.02.061","volume":"173","author":"Y Han","year":"2018","unstructured":"Han Y, Liu Q, Hou J, Gu Y, Zhang Y, Chen Z, et al. Tumor-induced generation of splenic Erythroblast-like Ter-cells promotes tumor progression. Cell. 2018;173:634\u201348.","journal-title":"Cell"},{"key":"1169_CR60","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/jnci\/77.3.733","volume":"77","author":"K Tanaka","year":"1986","unstructured":"Tanaka K, Koga Y, Taniguchi K, Kamikaseda K, Nihashi Y, Nomoto K. T-cell recruitment from the thymus to the spleen in tumor-bearing mice. II. Functional characteristics of recruited T -cells. J Natl Cancer Inst. 1986;77:733\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"1169_CR61","doi-asserted-by":"crossref","unstructured":"Lewis SM, Williams A, Eisenbarth SC. Structure and function of the immune system in the spleen. Sci Immunol. 2019;4:eaau6085.","DOI":"10.1126\/sciimmunol.aau6085"},{"key":"1169_CR62","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nri1669","volume":"5","author":"RE Mebius","year":"2005","unstructured":"Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol. 2005;5:606\u201316.","journal-title":"Nat Rev Immunol"},{"key":"1169_CR63","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nri.2017.11","volume":"17","author":"O Krenkel","year":"2017","unstructured":"Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol. 2017;17:306\u201321.","journal-title":"Nat Rev Immunol"},{"key":"1169_CR64","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41423-021-00791-9","volume":"19","author":"SK Wculek","year":"2022","unstructured":"Wculek SK, Dunphy G, Heras-Murillo I, Mastrangelo A, Sancho D. Metabolism of tissue macrophages in homeostasis and pathology. Cell Mol Immunol. 2022;19:384\u2013408.","journal-title":"Cell Mol Immunol"},{"key":"1169_CR65","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ctrv.2010.05.001","volume":"37","author":"DW Siemann","year":"2011","unstructured":"Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev. 2011;37:63\u201374.","journal-title":"Cancer Treat Rev"},{"key":"1169_CR66","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","volume":"5","author":"MZ Jin","year":"2020","unstructured":"Jin MZ, Jin WL. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020;5:166.","journal-title":"Signal Transduct Target Ther"},{"key":"1169_CR67","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27:1482\u201392.","journal-title":"Ann Oncol"},{"key":"1169_CR68","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s41563-020-0755-z","volume":"19","author":"B Ouyang","year":"2020","unstructured":"Ouyang B, Poon W, Zhang YN, Lin ZP, Kingston BR, Tavares AJ, et al. The dose threshold for nanoparticle tumour delivery. Nat Mater. 2020;19:1362\u201371.","journal-title":"Nat Mater"},{"key":"1169_CR69","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1126\/science.6836294","volume":"220","author":"RT Proffitt","year":"1983","unstructured":"Proffitt RT, Williams LE, Presant CA, Tin GW, Uliana JA, Gamble RC, et al. Liposoinal blockade of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles. Science. 1983;220:502\u20135.","journal-title":"Science"},{"key":"1169_CR70","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nantod.2014.12.003","volume":"10","author":"T Liu","year":"2015","unstructured":"Liu T, Choi H, Zhou R, Chen IW. RES blockade: a strategy for boosting efficiency of nanoparticle drug. Nano Today. 2015;10:11\u201321.","journal-title":"Nano Today"},{"key":"1169_CR71","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1081\/LPR-120004790","volume":"12","author":"J Szebeni","year":"2002","unstructured":"Szebeni J, Baranyi L, Savay S, Milosevits J, Bunger R, Laverman P, et al. Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res. 2002;12:165\u201372.","journal-title":"J Liposome Res"},{"key":"1169_CR72","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","volume":"341","author":"M Estape Senti","year":"2022","unstructured":"Estape Senti M, de Jongh CA, Dijkxhoorn K, Verhoef JJF, Szebeni J, Storm G, et al. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. J Control Release. 2022;341:475\u201386.","journal-title":"J Control Release"},{"key":"1169_CR73","doi-asserted-by":"publisher","first-page":"7808","DOI":"10.1021\/acsnano.9b07218","volume":"14","author":"E Chen","year":"2020","unstructured":"Chen E, Chen BM, Su YC, Chang YC, Cheng TL, Barenholz Y, et al. Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex. ACS Nano. 2020;14:7808\u201322.","journal-title":"ACS Nano"},{"key":"1169_CR74","doi-asserted-by":"crossref","unstructured":"Gabizon A. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42:419\u201336.","DOI":"10.2165\/00003088-200342050-00002"},{"key":"1169_CR75","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20\u201337.","journal-title":"Nat Rev Cancer"},{"key":"1169_CR76","doi-asserted-by":"publisher","first-page":"114079","DOI":"10.1016\/j.addr.2021.114079","volume":"180","author":"D Shi","year":"2022","unstructured":"Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA, et al. To PEGylate or not to PEGylate: immunological properties of nanomedicine\u2019s most popular component, polyethylene glycol and its alternatives. Adv Drug Deliv Rev. 2022;180:114079.","journal-title":"Adv Drug Deliv Rev"},{"key":"1169_CR77","unstructured":"Liposome Drug Products: Chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation, https:\/\/www.fda.gov\/media\/70837\/download (2018)."}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01169-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01169-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01169-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T09:03:22Z","timestamp":1706778202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01169-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1169"],"URL":"https:\/\/doi.org\/10.1038\/s41401-023-01169-5","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}